Special Report: KRAS Finding Changes Oncology Practice But Poses Profound Regulatory Dilemma
FDA Concerned About Data-Dredging In Drug-Diagnostic Applications
Government Offers Two Approval Standards For Assays: CLIA, FDA
FDA Ponders Standards For “Retrospective Prospective” Studies
ODAC Discussion: NCI’s Richard Simon Cautions About Rules Of Thumb
Trending Stories
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest
- In the Headlines: MD Anderson’s Pisters on doing “something gigantic for pediatric cancer”
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures - In weekly vigils, current and former NIH staff grieve the impact of Trump cuts
The Saturday gatherings at NIH’s Metro station are part graveside service, part street theater